[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511659":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":37,"responsibleParty":56,"collaborators":60,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pregnant women with Opioid Use Disorder (OUD)",null,"This study will enroll 100 pregnant women with OUD at UPMC with its high volumes",[13],"Drug: Buprenorphine\u002F Methadone exposure",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Buprenorphine\u002F Methadone exposure","Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.",[9],[21],"Opioid Use Disorder",[23],{"name":24,"affiliation":25,"role":26},"Ilana Hull, MD","Univrsity of Pittsburgh \u002F UPMC Magee Womens Hospital","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Amy Monroe, MPH, MBA","CONTACT","412-623-6382","monroeal@upmc.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Carly Riedmann, MPH","412-623-4147","riedmannca@upmc.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"UPMC Magee-Womens Hospital","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-79.99589,40.44062,{"lat":50,"lon":49},[53,55],{"name":24,"role":30,"phone":10,"phoneExt":10,"email":54},"hulli@upmc.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ilana Hull","Assistant Professor of Medicine",[61,64],{"name":62,"class":63},"National Institute on Drug Abuse (NIDA)","NIH",{"name":65,"class":66},"OpalGenix, Inc","INDUSTRY","100511659","predicting-and-preventing-adverse-maternal-and-child-outcomes-of-opioid-use-disorder-in-pregnancy-100511659",false,"NCT05942313","Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy","Inclusion Criteria:\n\n* Pregnant women with OUD and their infant\n* Currently on BUP\u002FMETH for OUD\n* Enrolled in prenatal opioid maintenance program\n* Age \\>18 years\n* Singleton pregnancy\n* Planned delivery at UPMC's Magee Womans Hospital\n* Positive opioid urine screen results\n\nExclusion Criteria:\n\n* Serious maternal medical illness as deemed by the PI that would make it challenging to comply with study procedures\n* HIV or AIDS\n* Known major fetal congenital abnormalities","FEMALE","18 Years",{"count":76,"type":77},100,"ESTIMATED","OBSERVATIONAL","This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.",[21,81],"Pregnancy Related","2026-08-04",{"date":84,"type":85},"2026-08-06","ACTUAL",{"date":87,"type":85},"2023-08-28",{"date":89,"type":77},"2026-12-01",{"name":58,"class":6},1]